MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism

Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1

(2015) Yangyang Ou et al.   GENE

Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance

(2015) Yunhua He et al.   LEUKEMIA RESEARCH

The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer

(2015) Xiaohong Xie et al.   TUMOR BIOLOGY

miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2

(2015) Y An et al.   Cell Death & Disease

PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop

(2015) Wenkang Luan et al.   Oncotarget

Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib

(2015) Ewelina Synowiec et al.   Biomed Research International

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines

(2015) Alba Ginés et al.   PLoS One

PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma

(2015) Wei-Ren Liu et al.   Oncotarget

Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells

(2014) Feifei Xu et al.   Cancer Cell International

Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation

(2014) Ranjita Misra et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Regulation and function of pyruvate kinase M2 in cancer

(2013) Weiwei Yang et al.   CANCER LETTERS

PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells

(2013) William J. Israelsen et al.   CELL

Diversifying microRNA sequence and function

(2013) Stefan L. Ameres et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting cellular metabolism to improve cancer therapeutics

(2013) Y Zhao et al.   Cell Death & Disease

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting cancer cell mitochondria as a therapeutic approach

(2012) Shijun Wen et al.   Future Medicinal Chemistry

Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells

(2011) Y. Zhou et al.   CANCER RESEARCH

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

(2011) Uzma Asghar et al.   JOURNAL OF HEPATOLOGY

MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation

(2011) Yong-Xi Song et al.   Molecular Cancer

Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma

(2010) Xiao-ting Liang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

MicroRNA control of signal transduction

(2010) Masafumi Inui et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib

(2009) Shoumei Bai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties

(2009) C Coulouarn et al.   ONCOGENE

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma

(2008) Wei-Chih Tsai et al.   HEPATOLOGY